Phase 2 Trial of 89 Zr-Deferoxamine-Daratumumab for CD38-targeted Immuno-PET/CT Detection of Multiple Myeloma.
Gary A Ulaner, Russ A Kuker, Benjamin Diamond et al.
✦ AI-curated · Sources linked
In 30 seconds
This prospective phase 2 trial compared CD38-targeted 89Zr-DFO-daratumumab immuno-PET/CT with standard-of-care 18F-FDG PET/CT in 60 participants with multiple myeloma. At least one positive lesion was detected in 43% (26 of 60) with the investigational scan and 47% (28 of 60) with FDG PET/CT; overall detection did not differ (P = .81). However, immuno-PET/CT alone identified active myeloma in 13% (eight of 60) of participants, with subsequent biopsy confirmation.
Key findings
- At least one positive lesion was seen in 43% (26 of 60) with 89Zr-DFO-daratumumab PET/CT and 47% (28 of 60) with 18F-FDG PET/CT.
- Overall disease detection did not differ between imaging modalities (P = .81).
- Immuno-PET/CT alone detected active myeloma in 13% (eight of 60) of participants; subsequent biopsy confirmed the disease.
Why it matters
The findings suggest that CD38-targeted immuno-PET/CT may reveal active myeloma in some participants whose FDG PET/CT shows no disease, despite similar overall detection rates. This potential complementary role could be relevant when imaging findings are negative or discordant, while the study does not establish broader diagnostic or outcome benefits.
What to keep in mind
The study included 60 participants, and the abstract reports detection findings rather than effects on patient outcomes.